Core Laboratories Inc. CLB
Oilfield Services/Equipment · IPO 2023 · data as of November 13, 2026
Core Laboratories Inc. (CLB) is a energy company listed in the US with a market value of about $417M. In the twelve months to September 30, 2026 it had revenue of $517M and net income of $16M, a net margin of 3.0%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a P/E of 26.8, a price to free cash flow of 40.3, a 5-year average ROIC of 10%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 57% below the current price.
About Core Laboratories
Core Laboratories is listed in the US and classified in oilfield services/equipment, IPO year 2023. Revenue went from $470M in 2021 to $527M in 2025, growth of about 2.9% a year. It was profitable in 5 of the last 5 years in our data.
Score: 1.6 / 5
Checks passed
- 3-year free cash flow growth above 10% a year
- Profitable 5 years in a row
- Positive free cash flow
- Interest covered more than 5 times
- Liabilities below 60% of assets
- Pays a dividend
- Dividend 3 years in a row
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $517M | $527M | $524M | $510M | $490M | $470M |
| Net income | $16M | $30M | $31M | $37M | $19M | $20M |
| Free cash flow | $10M | $26M | $44M | $14M | $15M | $23M |
| EPS (diluted) | $0.34 | $0.63 | $0.66 | $0.77 | $0.42 | $0.42 |
| Net margin | 3.0% | 5.6% | 6.0% | 7.2% | 4.0% | 4.2% |
| ROIC | — | 8.6% | 9.5% | 11.1% | 6.7% | 15.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $15.00, 65% above the current price; targets range from $11.00 to $21.00; the consensus rating is “none”; expected EPS is $0.51 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Core Laboratories’s P/E ratio?
About 26.8, based on the last twelve months of diluted earnings per share (forward P/E about 14.1).
Is Core Laboratories stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 57% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Core Laboratories pay a dividend?
Yes. The dividend yield is about 0.44%, and it has paid dividends for 5 years in our data.
Is Core Laboratories a good stock to buy?
We do not give buy or sell advice. Core Laboratories scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.